Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2003-08-12
2010-11-16
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C530S359000, C530S327000, C530S326000, C424S185100, C424S193100, C514S002600
Reexamination Certificate
active
07833532
ABSTRACT:
The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.
REFERENCES:
patent: 5580563 (1996-12-01), Tam
patent: 5700910 (1997-12-01), Metzger et al.
patent: 6024964 (2000-02-01), Jung et al.
patent: WO-93/22343 (1993-11-01), None
Kaumaya, Journal of Molecular Recognition 6, 81-94, 1993.
Benmohamed, L., et al., “Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees,” Eur. J. Immunol, 1997, pp. 1242-1253, vol. 27.
Benmohamed, L., et al., “High immunogenicity in chimpanzees of peptides and lipopeptides derived from four newPlasmodium falciparumpre-erythrocytic molecules,” Vaccine 18, 2000, pp. 2843-2855.
Boeckler, C., et al., “Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes,” Eur. J. Immunol, 1999, pp. 2297-2308, vol. 29.
Deprez, B., et al., “Pimelautide or Trimexautide as Built-in Adjuvants Associated with an HIV-1-Derived Peptide: Synthesis and in Vivo Induction of Antibody and Virus-Specific Cytotoxic T-Lymphocyte-Mediated Response,” J. Med. Chem., 1995, pp. 459-465, vol. 38.
Deprez, B., et al., “Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL,” Vaccine, 1996, pp. 375-382, vol. 14, No. 5.
Deres, K., et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine,” Nature, Nov. 30, 1989, pp. 561-564, vol. 342.
Ghosh, S., et al., “Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines,” International Immunology, 1999, pp. 1103-1110, vol. 11.
Jung, G., et al., “Increased Production of Specific Antibodies by Presentation of the Antigen Determinants with Covalently Coupled Lipopeptide Mitogens,” Angew Chem, Int. Ed. Engl., 1985, pp. 872-273, No. 10.
Martinon, F., et al., “Immunization Of Mice With Lipopeptides Bypasses The Prerequisite For Adjuvant, Immune Response to Lipopeptides,” The Journal of Immunology, 1992, pp. 3416-3422, vol. 149, No. 10.
Metzger, J., et al., “Synthetic S-(2, 3-Dihydroxypropyl)-cysteinyl Peptides Derived from the N-terminus of the Cytochrome Submit of the Photoreaction Centre ofRhodopseudomonas viridisEnhance Murine Splenocyte Proliferation, Novel Synthetic Lipopeptides Activate Splenocytes,” Journal of Peptide Science, 1995, pp. 184-190, vol. 3.
Mühlradt, P., et al., “Isolation, Structure Elucidation, and Synthesis of a Macrophage Stimulatory Lipopeptide fromMycoplasma fermentansActing at Picomolar Concentration,” J. Exp. Med., Jun. 2, 1997, pp. 1951-1958, vol. 185, No. 11.
Mühlradt, P., et al., “Structure and Specific Activity of Macrophage-Stimulating Lipopeptides fromMycoplasma hyorhinis,” Infection and Immunity, Oct. 1998, pp. 4804-4810, vol. 66, No. 10.
Nardin, E. H., et al., “A Totally Synthetic Polyoxime Malaria Vaccine ContainingPlasmodium falciparumB Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types,” The Journal of Immunology, 2001, pp. 481-489, vol. 166.
Nardin, E. H., et al., “Plasmodium falciparumpolyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-Cell epitope of CS protein,” Vaccine, 1998, pp. 590-600, vol. 16, No. 6.
Obert, M., et al., “Protection of mice against SV40 tumours by Pam3Cys conjugated with SV40 T antigen-derived peptide, K(698)-T(708),” Vaccine, 1998, pp. 161-169, vol. 16, No. 2/3.
Sauzet, J.-P., et al., “Long-lasting anti-viral cytotixic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides,” Vaccine, 1995, pp. 1339-1345, vol. 13, No. 14.
Toyokuni, T., et al., “Synthetic Vaccines: Synthesis of a Dimeric Tn Antigen-Lipopeptide Conjugate that Elicits Immune Responses against Tn-Expressing Glycoproteins,” J. Am. Chem. Soc., 1994, pp. 395-396, vol. 116.
Wiesmüller, K.-H., et al., “Synthesis of the Mitogenic S-[2, 3-Bis(palmitoyloxy) propyl]-N-palmitoylpentapeptide fromEscherichia coliLipoprotein,” Hoppe-Seyler's Z. Physiol. Chem., 1983, pp. 593-606, Bd. 364.
Wiesmüller, K.-H., et al., “Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator,” Vaccine, Feb. 1989, pp. 29-33, vol. 7.
Deliyannis Georgia, et al., “Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus,” Journal of Virology, May 2002, pp. 4212-4221, vol. 76, No. 9.
Jackson, D.C., et al., “The Central Role Played by Peptides in the Immune Response and the Design of Peptide-Based Vaccines against Infectious Diseases and Cancer,” Current Drug Targets, 2002, pp. 175-196, vol. 2, No. 2.
Zeng Weiguang, et al., “Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptice vaccines,” Journal of Immunology, Nov. 1, 2002, pp. 4905-4912, vol. 169, No. 9.
Supplementary European Search Report, European Patent Application No. 03783852.1, Sep. 7, 2007, 9 Pages.
Jackson David
Zeng Weiguang
Fenwick & West LLP
Lukton David
The Council of The Queensland Institute of Medical Research
LandOfFree
Immunogenic lipopeptides comprising T-helper and cytotoxic T... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic lipopeptides comprising T-helper and cytotoxic T..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic lipopeptides comprising T-helper and cytotoxic T... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162767